European Commission grants zanidatamab Orphan Drug designation for gastric cancer

Zanidatamab is a HER2-targeted antibody that simultaneously binds two non-overlapping epitopes of HER2 (biparatopic binding), resulting in dual HER2 signal blockade, and increased binding and removal of HER2 protein from the cell surface.

Source:

Biospace Inc.